Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
907.32
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
4
Open
907.32
Bid (Size)
362.93 (2)
Ask (Size)
1,451.71 (2)
Prev. Close
907.32
Today's Range
907.32 - 907.32
52wk Range
684.80 - 998.33
Shares Outstanding
91,779,465
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
April 22, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
April 18, 2024
From
Kirby McInerney LLP
Via
GlobeNewswire
Performance
YTD
+0.26%
+0.26%
1 Month
-5.59%
-5.59%
3 Month
-4.95%
-4.95%
6 Month
+12.81%
+12.81%
1 Year
+13.84%
+13.84%
More News
Read More
Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
April 18, 2024
Via
Benzinga
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm
April 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today
April 17, 2024
Via
Benzinga
Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views
April 12, 2024
Via
Benzinga
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Via
Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
April 17, 2024
From
Law Offices of Frank R. Cruz
Via
Business Wire
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
April 11, 2024
Via
Benzinga
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
March 28, 2024
Via
Benzinga
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
March 26, 2024
Via
Benzinga
Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug
April 11, 2024
Via
Benzinga
Topics
Fraud
Exposures
Legal
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
April 11, 2024
From
Schall Law
Via
GlobeNewswire
Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity?
April 11, 2024
Via
Investor's Business Daily
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
April 07, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Should You Sell This Stock Following a Regulatory Roadblock?
April 05, 2024
Via
The Motley Fool
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
April 01, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
April 01, 2024
Via
Benzinga
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
March 28, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
March 28, 2024
Via
The Motley Fool
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
March 26, 2024
Via
InvestorPlace
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
March 25, 2024
Via
Benzinga
Exposures
Product Safety
Regeneron Provides Update on Biologics License Application for Odronextamab
March 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.